Literature DB >> 31933852

Interference from LncRNA SPRY4-IT1 restrains the proliferation, migration, and invasion of melanoma cells through inactivating MAPK pathway by up-regulating miR-22-3p.

Zhiqing Li1, Xuefeng Tang2, Song Duan3.   

Abstract

Melanoma is a common malignancy with a low survival rate worldwide. Long non-coding RNA Sprouty4-Intron 1 (SPRY4-IT1) is correlated with various cancers, including melanoma. Herein, the underlying molecular mechanisms of SPRY4-IT1 in melanoma were characterized. We found that SPRY4-IT1 level was upregulated in melanoma cells lines compared to the normal skin cells, while miR-22-3p was downregulated. According to of bioinformatics analysis, SPRY4-IT1 was a hypothetic target of miR-22-3p, and knockdown SPRY4-IT1 by sh-RNA (sh-SPRY4-IT1) markedly elevated the miR-22-3p level. Also, the target relationship was further confirmed by dual luciferase reporter assay. In addition, low-expression of SPRY4-IT1 impeded cell proliferation, invasion, migration, and epithelial-mesenchymal transition. Furthermore, western blot assay indicated that the enhanced miR-22-3p further decelerated the phosphorylation of p38MAPK, MAPKAPK and Hsp27, which indicates that miR-22-3p could inactivate the p38MAPK/MAPKAPK/Hsp27 signaling pathway. Overall, our results show that sh-SPRY4-IT1 inhibits cell proliferation and motility through inactivating MAPK signaling by up-regulating miR-22-3p. Therefore, designing targeted drugs against SPRY4-IT1 provides a new direction for the treatment of melanoma. IJCEP
Copyright © 2019.

Entities:  

Keywords:  MAPK pathway; Melanoma; SPRY4-IT1; miR-22-3p; motility; proliferation

Year:  2019        PMID: 31933852      PMCID: PMC6945084     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  33 in total

1.  Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.

Authors:  Neveen Abd El Moneim Hussein; Zenat A El Kholy; Medhat M Anwar; Mohamed A Ahmad; Shaymaa M Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-15       Impact factor: 4.553

2.  Sulfated polysaccharide of Sepiella Maindroni ink inhibits the migration, invasion and matrix metalloproteinase-2 expression through suppressing EGFR-mediated p38/MAPK and PI3K/Akt/mTOR signaling pathways in SKOV-3 cells.

Authors:  Wenjie Jiang; Yanna Cheng; Na Zhao; Lian Li; Yikang Shi; Aizhen Zong; Fengshan Wang
Journal:  Int J Biol Macromol       Date:  2017-09-09       Impact factor: 6.953

3.  miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1.

Authors:  Hafiz M Ahmad; Pamchui Muiwo; Suganthi S Ramachandran; Priyatama Pandey; Yogendra K Gupta; Lalit Kumar; Ritu Kulshreshtha; Alok Bhattacharya
Journal:  FEBS J       Date:  2014-07-31       Impact factor: 5.542

4.  A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.

Authors:  Ling-Min Kong; Cheng-Gong Liao; Yang Zhang; Jing Xu; Yu Li; Wan Huang; Yi Zhang; Huijie Bian; Zhi-Nan Chen
Journal:  Cancer Res       Date:  2014-06-06       Impact factor: 12.701

5.  Elevated Hepatic miR-22-3p Expression Impairs Gluconeogenesis by Silencing the Wnt-Responsive Transcription Factor Tcf7.

Authors:  Kirandeep Kaur; Saurabh Vig; Rohit Srivastava; Akansha Mishra; Vijay Pal Singh; Arvind K Srivastava; Malabika Datta
Journal:  Diabetes       Date:  2015-07-20       Impact factor: 9.461

Review 6.  Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.

Authors:  D Grossman; D C Altieri
Journal:  Cancer Metastasis Rev       Date:  2001       Impact factor: 9.264

7.  Response of MiRNA-22-3p and MiRNA-149-5p to Folate Deficiency and the Differential Regulation of MTHFR Expression in Normal and Cancerous Human Hepatocytes.

Authors:  Chao Li; Juan Ni; Yao-Xian Liu; Han Wang; Zi-Qing Liang; Xu Wang
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

8.  Upregulation of UHRF1 promotes the progression of melanoma by inducing cell proliferation.

Authors:  Chuanyuan Wei; Nanhang Lu; Lu Wang; Yong Zhang; Zihao Feng; Yanwen Yang; Fazhi Qi; Jianying Gu
Journal:  Oncol Rep       Date:  2018-04-04       Impact factor: 3.906

9.  EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.

Authors:  M Sun; X-H Liu; K-H Lu; F-Q Nie; R Xia; R Kong; J-S Yang; T-P Xu; Y-W Liu; Y-F Zou; B-B Lu; R Yin; E-B Zhang; L Xu; W De; Z-X Wang
Journal:  Cell Death Dis       Date:  2014-06-26       Impact factor: 8.469

10.  Long non-coding RNA SPRY4-IT1 promotes cell proliferation and invasion by regulation of Cdc20 in pancreatic cancer cells.

Authors:  Wenhao Guo; Kunhong Zhong; Heng Wei; Chunlai Nie; Zhu Yuan
Journal:  PLoS One       Date:  2018-02-28       Impact factor: 3.240

View more
  5 in total

Review 1.  Long non-coding RNAs involved in different steps of cancer metastasis.

Authors:  P Suman; Y Chhichholiya; P Kaur; S Ghosh; A Munshi
Journal:  Clin Transl Oncol       Date:  2022-02-04       Impact factor: 3.405

Review 2.  A Review on the Role of SPRY4-IT1 in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Mohammad Taheri; Seyedpouzhia Shojaei
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

Review 3.  Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process.

Authors:  Marine Melixetian; Pier Giuseppe Pelicci; Luisa Lanfrancone
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

4.  SPRY4-IT1 promotes survival of colorectal cancer cells through regulating PDK1-mediated glycolysis.

Authors:  Shengyuan Liu; Feng Huang; Qing Ye; Yangming Li; Jinhu Chen; Hong Huang
Journal:  Anim Cells Syst (Seoul)       Date:  2020-06-25       Impact factor: 1.815

Review 5.  The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma.

Authors:  Barbara Montico; Giorgio Giurato; Giovanni Pecoraro; Annamaria Salvati; Alessia Covre; Francesca Colizzi; Agostino Steffan; Alessandro Weisz; Michele Maio; Luca Sigalotti; Elisabetta Fratta
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.